Publication Type |
pre-print |
School or College |
School of Medicine |
Department |
Pediatrics |
Creator |
Frazer, John K. |
Other Author |
Goldman, S.; Smith, L.; Galardy, P.; Perkins, S. L.; Sanger, W.; Anderson, J. R.; Gross, T. G.; Weinstein, H.; Harrison, L.; Shiramizu, B.; Barth, M.; Cairo, M. S. |
Title |
Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a childrens oncology group report |
Date |
2014-01-01 |
Description |
Approximately 1 in 4 children and adolescents with de-novo mature and Burkitt lymphoma (BL) present with high-risk disease that is either mature B-cell leukaemia (bone marrow ≥ 25% blasts [BM]) and/or have central nervous system (CNS) involvement. Both the Berlin-Frankfurt- Münster (BFM) and French-American-British (FAB) international cooperative studies have unsuccessfully attempted to reduce the overall burden of chemotherapy in this high risk group of patients. In the FAB 96 study, a randomized attempt to reduce the dose of cytarabine during consolidation and eliminate three final cycles of maintenance was halted early due to inferior event-free survival (EFS) (Cairo, et al 2012, Cairo, et al concluded that reducing the infusion duration of methotrexate from 24 to 4 hours led to significantly inferior EFS in high risk (R3/R4) patients.(Woessmann, et al 2005) Subsets of children with BL, such as those with poor response to initial reduction, complex karyotypes, and those with combined BM and CNS disease, have a significantly worse prognosis (Cairo, et al 2012, Cairo, et al 2007, Poirel, et al 2009). |
Type |
Text |
Publisher |
Wiley-Blackwell |
Volume |
167 |
Issue |
3 |
First Page |
394 |
Last Page |
401 |
Language |
eng |
Bibliographic Citation |
Goldman, S., Smith, L., Galardy, P., Perkins, S.L., Frazer, J.K., Sanger, W., Anderson, J.R., Gross, T. G., Weinstein, H., Harrison, L., Shiramizu, B., Barth, M., & Cairo, M. S. (2014). Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a childrens oncology group report. British Journal of Haematology, 167(3), 394-401. |
Rights Management |
(c) Wiley-Blackwell The definitive version is available at www3.interscience.wiley.com ; This is the pre-peer reviewed version of the following article: Goldman, S., Smith, L., Galardy, P., Perkins, S.L., Frazer, J.K., Sanger, W., Anderson, J.R., Gross, T. G., Weinstein, H., Harrison, L., Shiramizu, B., Barth, M., & Cairo, M. S. (2014). Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive burkitt lymphoma/leukaemia: a childrens oncology group report. British Journal of Haematology, 167(3), 394-401, which has been published in final form at doi: 10.1111/bjh.13040. |
Format Medium |
application/pdf |
Format Extent |
1,586,834 bytes |
Identifier |
uspace,19136 |
ARK |
ark:/87278/s6060r31 |
Setname |
ir_uspace |
ID |
712781 |
Reference URL |
https://collections.lib.utah.edu/ark:/87278/s6060r31 |